Nitric oxide and the mediation of the hemodynamic effects of growth hormone in humans

Journal of Endocrinological Investigation

Volumn 22, Issue 5 SUPPL., 1999, Pages 75-81

  Boger R H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cyclic GMP; Endothelium; Growth hormone; Hemodynamic effects; IGF I; Nitric oxide syntheses

Indexed keywords

ARGININE; HUMAN GROWTH HORMONE; NITRIC OXIDE; SOMATOMEDIN C;

CARDIOVASCULAR FUNCTION; HEMODYNAMICS; HUMAN; PHYSIOLOGY; REVIEW;

ARGININE; CARDIOVASCULAR PHYSIOLOGY; HEMODYNAMIC PROCESSES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NITRIC OXIDE;

EID: 0032602417     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288: 373.
2. Furchgott R.F. The role of the endothelium in the responses of vascular smooth muscle to drugs. Annu. Rev. Pharmacol. Toxicol. 1984, 24: 175.
3. Palmer R.M.J., Ferrige A.G., Moncada S. Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327: 524.
4. Böger R.H., Bode-Böger S.M., Frölich J.C. The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis 1996, 127: 1.
5. Moncada S., Higgs E.A. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 1993, 329: 2002.
6. Förstermann U., Closs E.I., Pollock J.S., Nakane M., Schwarz P., Gath I., Kleinert H. Nitric oxide synthase isoenzymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994, 23: 1121.
7. Griffith T.M., Edwards D.H., Lewis M.J., Newby A.C., Henderson A.H. The nature of the endothelium-derived vascular relaxant factor. Nature 1984, 308: 645.
8. Ignarro L.J. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu. Rev. Pharmacol. Toxicol. 1990, 30: 535.
9. - excretion as an indicator of nitric oxide formation in vivo during oral administration of L-arginine or L-NAME in rats. Clin. Exp. Pharmacol. Physiol. 1996, 23: 11.
10. Bode-Böger S.M., Böger R.H., Alfke H., Heinzel D., Tsikas D., Creutzig A., Alexander K., Frölich J.C. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation 1996, 93: 85.
11. Wolf A., Zalpour C., Theilmeier G., Wang B.Y., Ma A., Anderson B., Tsao P.S., Cooke J.P. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J. Am. Coll. Cardiol. 1997, 29: 479.
12. Kubes P., Suzuki M., Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. U.S.A. 1991, 88: 4651.
13. Garg U.C., Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 1989, 83: 1774.
14. Böger R.H., Bode-Böger S.M., Kienke S., Stan A.C., Nafe R., Frölich J.C. Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits. Atherosclerosis 1998, 136: 67.
15. Böger R.H., Bode-Böger S.M., Mügge A., Kienke S., Brandes R., Dwenger A., Frölich J.C. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 1995, 117: 273.
16. Hogg N., Kalyanaraman B., Joseph J., Struck A., Parthasarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett. 1993, 334: 170.
17. Cooke J.P., Dzau V.J. Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation 1997, 96: 379.
18. Daughaday W.H., Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev. 1989, 10: 68.
19. Saccà L., Cittadini A., Fazio S. Growth hormone and the heart. Endocr. Rev. 1994, 15: 555.
20. Landin-Wilhelmsen K., Wilhelmsen L, Lappas G., Rosén T., Lindstedt G., Lundberg P.A., Bengtsson B.-Å. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin. Endocrinol. 1994, 41: 351.
21. Bar R.S., Boes M., Dake B.L., Booth B.A., Henley S.A., Sandra A. Insulin, insulin-like growth factors, and vascular endothelium. Am. J. Med. 1988, 85 (Suppl. 5a): 59.
22. Haylor J., Singh I., El Nahas A.M. Nitric oxide inhibitor prevents vasodilation by insulin-like growth factor I. Kidney Int. 1991, 39: 333.